All Stories

  1. Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN
  2. Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis: Table 1.
  3. Pauci Immune crescentic glomerulonephritis in a patient with T-cell lymphoma and argyria
  4. Treatment with Quinoline-3-carboxamide does not successfully prevent immune-mediated glomerulonephritis in mice
  5. Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis
  6. Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome
  7. Practical Immunosuppression Guidelines for Patients with Glomerulonephritis
  8. Goodpasture’s or Anti-glomerular Basement Membrane (GBM) Disease
  9. Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?
  10. Goodpasture Syndrome and Other Antiglomerular Basement Membrane Diseases
  11. The kidney
  12. Anti-glomerular Basement Membrane Disease
  13. Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis
  14. Diabetic Nephropathy
  15. Proteinase-3 Antineutrophil Cytoplasm Antibody Positivity in Patients Without Primary Systemic Vasculitis
  16. Treating Glomerulonephritis
  17. Rheumatological diseases associated with interstitial nephritis
  18. The Renal Biopsy
  19. Animal models of antineutrophil cytoplasm antibody-associated vasculitis
  20. Rituximab in Refractory Ophthalmic Wegener's Granulomatosis
  21. B-Cell-Depleting Agents: The Chicken and the Egg
  22. ANCA comes of age—but with caveats
  23. Obesity and Kidney Disease: A Call to Action
  24. Update on antiglomerular basement membrane disease
  25. Clinical Trials in Glomerulonephritis: Quality Needed, Not Quantity
  26. The Authors Reply:
  27. Management of ANCA-associated vasculitis: Current trends and future prospects
  28. A Better Nightʼs Sleep in CKD
  29. Non–hepatitis virus associated mixed essential cryoglobulinemia
  30. Management of Acute Kidney Problems: Indications for Renal Biopsy in Acute Renal Disease
  31. Shining a LAMP on pauci-immune focal segmental glomerulonephritis
  32. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis
  33. Lupus Nephritis: The Ghosts of Treatments Past, Present, and Future
  34. Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
  35. Autosomal Dominant Polycystic Kidney Disease: Opening the Floodgates of Therapy?
  36. Goodpasture’s Syndrome and Other Anti–Glomerular Basement Membrane Disease
  37. Aldosterone Blockade: Need to Investigate Use in Glomerulonephritis
  38. To Infinity and Beyond: Achieving Clinical Immunological Tolerance
  39. How high is the risk of ANCA-associated vasculitis recurring after renal transplantation?
  40. Renal biopsy
  41. Ocular manifestations of Wegener’s granulomatosis
  42. Chapter 6 Renal Toxicities Associated with Immunomodulatory Drugs
  43. Drug Insight: rituximab in renal disease and transplantation
  44. Disease models of rapidly progressive glomerulonephritis
  45. Alternative T-Cell Costimulatory Pathways in Transplant Rejection and Tolerance Induction: Hierarchy or Redundancy?
  46. HAEMOLYTIC URAEMIC SYNDROME AND THROMBOTIC THROMBOCYTOPAENIC PURPURA
  47. Challenges for the translation of T cell costimulatory blockade therapies to the clinic
  48. Immunology of anti-glomerular basement membrane disease
  49. Kidney transplantation principles and practice, 5th edition
  50. Challenges to achieving clinical transplantation tolerance
  51. Goodpasture's disease
  52. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome
  53. Tuberous Sclerosis
  54. MULTIPLE CLADOSPORIUM BRAIN ABSCESSES IN A RENAL TRANSPLANT PATIENT
  55. Desipramine reversal of chloroquine resistance in wild isolates of Plasmodium falciparum
  56. Tolerance: A Review of Its Mechanisms in the Transplant Setting
  57. In Vitro Assays for Immune Monitoring in Transplantation
  58. Faculty of 1000 evaluation for Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.